


Product Details

Product name:	Anti-IL-17 & IL-17F & Serum Albumin (Sonelokimab Biosimilar)	SKU:	BIO0964SM
Target Name:	IL-17 & IL-17F & Serum Albumin	Size:	100ug/ 1mg/ 5mg
Target Uniprot:	Q16552 & Q96PD4 & P02768	Concentration:	Lyophilized
Clone#:	Sonelokimab (Trispecific)	Isotype:	VHH-VHH-VHH
Reactivity:	Human	Calculated M.W.:	40.93 kDa
Application:	ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<0.001 EU/ug
Formulation:	100 mM Pro-Ac 20mM Arg pH 5.0	Conjugation:	None
Storage:	-20°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.	Expression System:	CHO
Reconstitution:	Dissolve with sterile ddH₂O	Purification:	Protein A


Data

Purity: SDS-PAGE




Anti-IL-17 & IL-17F & Serum Albumin Reference Antibody (Sonelokimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity: SEC-HPLC




The purity of Anti-IL-17 & IL-17F & Serum Albumin Reference Antibody (Sonelokimab) is 98.70%, determined by SEC-HPLC.

ELISA



Sonelokimab bound to IL-17F protein, and then rebounded to secondary antibodies (Anti-human-IgG-His-HRP), and read OD450. As shown in fig, Sonelokimab bound in hu-IL-17F-Fc, and the EC50 was 0.009 nM.


ELISA



Sonelokimab bound to HSA protein, and then rebounded to secondary antibodies (Anti-human-IgG-His-HRP), and read OD450. As shown in fig, Sonelokimab bound in hu-HSA-Fc, and the EC50 was 0.022nM.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Functional assay



Co-incubation of NHDF cells with TNF- α and IL-17A protein, then with the addition of Sonelokimab and incubated for 24 hours. IL-6 was measured by ELISA. As shown in fig 3, Sonelokimab can neutralize IL17-A-induced IL-6 factor secretion, and the IC50 was 2.877 nM.